Researchers have pinpointed Jagged-2, a signaling protein, as a potential therapeutic target for slowing or halting the progression of pulmonary arterial hypertension (PAH), based on a rat study. Suppressing Jagged-2 in a rat model reversed various processes that drive PAH progression, including inflammation and oxidative stress, a form of…
Read more
Two Phase 3 clinical trials are now recruiting participants to test Tenax Therapeutics‘ experimental therapy TNX-103 (oral levosimendan) in people with pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF). Tenax said its ongoing Phase 3 trial, LEVEL (NCT05983250), is expected to finish enrollment next year.
Uptravi (selexipag) may reduce blood pressure in the lungs of children with pulmonary arterial hypertension (PAH) and help them perform physical tasks, according to a meta-analysis. However, more long-term studies are still needed to confirm these benefits. The study, “Efficacy and Tolerability of Selexipag in…
Get regular updates to your inbox.
